It's the Technology. End of Story
Over a career that has spanned nearly 40 years, Bob Reiss has built a track record rivaled by few device executives, with senior positions at Sherwood Medical, Alza, Imed, ACS and Interventional Technoloiges. Reiss's most memorable stint: as one of the leaders of ACS, he solved a complex manufacturing problem that helped make angioplasty a common procedure and launched the interventional cardiology revolution. Common to all of Reiss's efforts: the notion that success in medical devices is fundamentally about technology and not, despite the importance of distribution and adoption issues, about marketing.
You may also be interested in...
In recent years, evidence-based medicine has had an important influence on cardiovascular devices, but it's easy to overlook the staying power of subjective judgment. At a session on "What's the Science on Niche Devices?" held during this year's American Heart Association meeting, the cardiologist-audience clearly didn't seem deterred from using certain devices such as DCA and rotoblators, despite equivical or mediocre results in clinical trials.
Innovative device companies have always had to contend with the Sword of Damocles of unexpected technological obsolescence, but for would-be developers of interventional devices for the prevention of restenosis, the sword is dangling perilously close. In the RAVEL trial, a 238-patient clinical trial on a drug eluting stent, treated patients experienced 0% restenosis compared to 26% in the control group. Now, device developers with alternatives to stents reposition themselves to sustain businesses in the face of potentially shrinking target markets. Many argue that they will serve certain applications better than stents; others hope to work with drug-coated stents to enhance performance, many believe that economics will leave room for alternative approaches, and still others are getting out of the coronary business entirely.
Although oncology remained strong, Japanese major says it saw multiple impacts from the pandemic, including on hospital visits and clinical trial recruitment, and has already cut its full-year guidance.